Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus rhamnosus GG (LGG) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/March/2019, 6.41 pm

Probiotic-based therapy for diabetes: Probiotic bifidobacterium CECT 7765  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 5/March/2019, 6.35 pm
March 5, 2019
Molecular therapy for Pulmonary arterial hypertension: Lactolose (brand name: Cholac, Generlac, Consulose, Duphalac, others) inhibits the development of pulmonary arterial hypertension (PAH) via down-regulation of its target gene Notch3, 6/March/2019, 9.41 pm
March 6, 2019
Show all

The significance of the study:

Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in the US succumb to this disease; (3) obesity and type 2 diabetes are risk factor for the development of NAFLD;  and (4) the global economic cost spent for NAFLD is enormous, there is an urgent need to find: (i) a way to decrease cholesterol deposition in liver; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, NAFLD.


Research findings to Therapeutic opportunity:

This study suggests a probiotic-based therapy for lowering cholesterol and triglyceride levels, and to treat Non-alcoholic fatty liver disease (NAFLD).

Probiotic Lactobacillus rhamnosus GG (LGG), by increasing the expression of its target gene, it may suppress the expression of HMGCR (Fig.1). Thereby, it may: (1) decrease Triglycerides, free cholesterol, and total cholesterol levels; (2) attenuate lipid deposition in the liver; and (3) inhibit progression to NAFLD (Fig. 1). Thus, probiotic Lactobacillus rhamnosus GG (LGG), either alone or in combination with other drugs, may be used to treat NAFLD.

Figure 1. Mechanistic insights into how Lactobacillus Paracasei OFS 0291 (LP-0291) decreases the expression of HMGCR, lowers cholesterol levels, decreases triglyceride levels, and NAFLD.

[/caption]


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Lactobacillus rhamnosus GG (LGG) decrease the expression of HMGCR and prevent NAFLD?

Amount: $750#

# Research cooperation

For purchase and payment details, you may reach us at info@genomediscovery.org


References:

Web: http://genomediscovery.org or http://newbioideas.com

Citation: Boominathan, L., Probiotic-based therapy for lowering cholesterol, and triglycerides levels: Lactobacillus rhamnosus GG (LGG) decreases the levels of HMGCR,  triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD), via up-regulation of its target gene, 5/March/2019, 6.41 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, kindly drop us a line at info@genomediscovery.org

Comments are closed.